A little more than two months after filing for approval of Vivitrex, Alkermes Inc. partnered the alcohol-dependence drug with Cephalon Inc. in a 50-50 profit-sharing deal worth an additional $480 million in up-front and milestone payments. (BioWorld Today)

PHILADELPHIA - A disease of epidemic proportions hit Room 103A at the Pennsylvania Convention Center on Wednesday, the last day of the Biotechnology Industry Organization's annual international convention here. (BioWorld Today)